Category: Today’s Highlights
Arena's Successful Pulmonary Arterial Hypertension Drug. Novartis CAR-T Product Review for Approval Tomorrow
Arena (ARNA) announced positive Phase 2 clinical trial results for its drug ralinepag 1 for pulmonary arterial hypertension (PAH). In the 61-patient study, the primary efficacy analysis demonstrated a statistically significant absolute change from baseline in pulmonary vascular resistance (PVR) compared...
Read More
July 11, 2017
0
Merck's superior accomplishments
Merck (MRK) announced its Q4 2018 financial results . The firm outperformed itself and delighted us with regard to picking its stock on time. Merck compensated those who bet on it the day it was added to the Prohost...
Read More
February 1, 2019
0
Halozyme signs another license agreement this time with argenx
Halozyme Therapeutics (HALO) and argenx (ARGX) announced a global collaboration and license agreement offering argenx the right to use Halozyme's ENHANZE® drug delivery technology to develop multiple subcutaneous product formulations for current or future argenx product candidates. The agreement...
Read More
February 5, 2019
0
ImmunoGen's Report and Standing. Why Biogen Is Experiencing a Selloff
ImmunoGen & Biogen News About ImmunoGen ImmunoGen (IMGN) is a creator and developer of antibody-drug conjugates (ADCs) aimed at improving cancer treatments. ImmunoGen aims to disrupt the progression of cancer through its conjugated targeted monoclonal antibodies. ImmunoGen’s lead ADC...
Read More
February 8, 2019
0
Portola: On the right track
Portola Pharmaceuticals (PTLA) announced full results from ANNEXA-4, Phase 3b/4 trial of its Factor Xa inhibitor antidote Andexxa ® in patients experiencing acute major bleeding while taking a Factor Xa inhibitor. The data were presented at the International Stroke Conference 2019 and...
Read More
February 12, 2019
0
Why Portola couldn’t flex its muscles or use them yet
All the buying and selling of Portola (PTLA) will not make any sense to us until the firm fulfills its obligations towards what is required by the authorities, by health care and by private third-party payers. So, in the reporting...
Read More
August 9, 2018
0
Regeneron: Two good news and a rebound on the road
The FDA Approves Regeneron’s Product EyLea® (aflibercept) sBLA in Wet Age-Related Macular Degeneration Regeneron (REGN) has two good news. The first is from one of its approved products, EYLEA ® announcing that the U.S. Food and Drug Administration(FDA) has approved a...
Read More
August 17, 2018
0
Vertex: A Cystic Fibrosis Institution with a Bright Future
Yesterday, Wednesday July 19, Vertex’s (VRTX) stock added over 20% to its value, recording a new all time high. Why? On Tuesday the firm announced a better than technical analysts’ and its own expectations’ results in three trials testing its...
Read More
July 20, 2017
0
Exelixis' excellent scientific and financial accomplishments
Exelixis’ (EXEL) financial results for the fourth quarter and full year 2018 are as inspiring as they are outstanding compared to many other small biotech firms that succeeded in putting products on the market. Revenues Exelixis total revenues ...
Read More
February 13, 2019
0
Theravance Biopharma Has Good News for COPD Patients
Theravance Biopharma (TBPH) and Mylan N.V. (MYL) announced positive results from a 12-month Phase 3 safety study of revefenacin (TD-4208). The drug is an investigational long-acting muscarinic antagonist (LAMA) - a proposed once-daily, NEBULIZED bronchodilator for chronic obstructive pulmonary disease...
Read More
July 21, 2017
0
Search ProhostBiotech
Popular Links
23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)